| Tardive Dyskinesia
Ingrezza vs Austedo XR
Side-by-side clinical, coverage, and cost comparison for tardive dyskinesia.Deep comparison between: Ingrezza vs Austedo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAustedo has a higher rate of injection site reactions vs Ingrezza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Austedo but not Ingrezza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ingrezza
Austedo
At A Glance
Oral
Once daily
VMAT2 inhibitor
Oral
Once or twice daily
VMAT2 inhibitor
Indications
- Tardive Dyskinesia
- Huntington Disease
- Huntington Disease
- Tardive Dyskinesia
Dosing
Tardive Dyskinesia Initial dose 40 mg once daily; increase to recommended dose of 80 mg once daily after one week; 40 mg or 60 mg once daily may be considered based on response and tolerability.
Huntington Disease Initial dose 40 mg once daily; increase in 20 mg increments every two weeks to recommended dose of 80 mg once daily; 40 mg or 60 mg once daily may be considered based on response and tolerability.
Huntington Disease, Tardive Dyskinesia Starting dose 12 mg/day (AUSTEDO XR: 12 mg once daily; AUSTEDO: 6 mg twice daily); titrate weekly in 6 mg/day increments to a maximum of 48 mg/day; do not exceed 36 mg/day with strong CYP2D6 inhibitors or in poor CYP2D6 metabolizers.
Contraindications
- History of hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE
- Huntington's disease with suicidality, or untreated or inadequately treated depression
- Hepatic impairment
- Concomitant reserpine; at least 20 days must elapse after stopping reserpine before initiating AUSTEDO XR or AUSTEDO
- Concomitant MAOI use, or within 14 days of discontinuing an MAOI
- Concomitant tetrabenazine or valbenazine use
Adverse Reactions
Most common (>=2%) - Tardive Dyskinesia Somnolence/fatigue/sedation, anticholinergic effects, balance disorders/fall, headache, akathisia, vomiting, nausea, arthralgia
Most common (>=4%) - Huntington Disease chorea Somnolence/lethargy/sedation, fatigue, urticaria, rash, insomnia, akathisia, depression, diarrhea, nausea, back pain
Serious Depression and suicidal ideation (Huntington Disease), hypersensitivity reactions, somnolence and sedation, QT prolongation, neuroleptic malignant syndrome, parkinsonism
Postmarketing Hypersensitivity reactions including allergic dermatitis and pruritis
Most common in Huntington Disease (>8%) somnolence, diarrhea, dry mouth, fatigue
Most common in Tardive Dyskinesia (>3%) nasopharyngitis, insomnia
Serious depression and suicidality in HD patients, QTc prolongation, neuroleptic malignant syndrome, akathisia/agitation/restlessness, parkinsonism, sedation and somnolence, hyperprolactinemia
Pharmacology
VMAT2 inhibitor; valbenazine reversibly inhibits vesicular monoamine transporter 2 (VMAT2), regulating monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release, and is converted to active metabolite [+]-alpha-dihydrotetrabenazine ([+]-alpha-HTBZ), which also binds VMAT2 with high affinity (Ki ~3 nM).
Deutetrabenazine is a reversible vesicular monoamine transporter 2 (VMAT2) inhibitor; its active metabolites (alpha-HTBZ and beta-HTBZ) deplete monoamine stores by inhibiting uptake of dopamine, serotonin, norepinephrine, and histamine into synaptic vesicles, with the precise mechanism in treating tardive dyskinesia and Huntington's chorea believed related to this monoamine-depleting effect.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ingrezza
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (2/12)
Austedo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Ingrezza
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (0/8) · Qty limit (7/8)
Austedo
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Ingrezza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Austedo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Movement Disorders - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Huntington's Disease - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IngrezzaView full Ingrezza profile
AustedoView full Austedo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.